口服避孕药在子宫内膜异位症治疗中的作用  

The effect of oral contraceptives in treatment of endometriosis

作　　者：范俊[1] 栾少红[1] 李晓林[1] 孙宝治[1] 

机构地区：[1]青岛市市立医院妇科,山东青岛266071

出　　处：《中国计划生育和妇产科》2013年第2期73-75,共3页Chinese Journal of Family Planning & Gynecotokology

摘　　要：目的观察短效口服避孕药治疗子宫内膜异位症的疗效及不良反应。方法选择2008～2010年在青岛市市立医院妇科门诊就诊的子宫内膜异位症有症状患者43例。于月经周期第5天开始口服屈螺酮炔雌醇片（商品名：优思明），周期用药，共用9个周期。用药前及用药9个周期后使用视觉模拟（visualanaloguescale，VAS）评分法进行疼痛评分，B超测量卵巢内膜异位囊肿大小，测定血糖类抗原125（cancerantigen125，CA125）水平，进行血常规及肝、肾功能检测。用药期间记录不良反应。结果患者用药后痛经疼痛评分及血CAl25水平较用药前明显降低（P〈0．05）；性交痛及盆腔痛评分及卵巢子宫内膜样囊肿大小用药前后无明显差异（P〉0．05）。所有患者用药前后血常规及肝肾功均无异常。无因不良反应而停药者。结论短效口服避孕药治疗子宫内膜异位症疗效肯定、不良反应低，特别适用于痛经明显、异位囊肿较小者。Objective To observe the efficacy and side effects of oral contraceptive for treating endometriosis. Methods Clinical data was from 43 endometriosis patients with symptoms between January 2008 and December 2010. All patients were taken Drospirenone and ethinylestradiol tablets （Yasmin） on the fifth day of menstrual cycle for 9cycles. The visual analogue scale score （VAS） score, serum cancer antigen 125 （ CA125 ） level, blood routine examination ,liver and kidney function,endometriosis mass and side effects were recorded before and after treatment. Results The VAS score for Dysmenorrhea, serum CA125 level after treatment was significantly lower than that of before treatment and the difference was significant （ P 〈 0. 05 ）. VAS score or pelvic pain VAS score, size of mass between before and after treatment was no significant（ P 〉 0. 05 ）. After treatment, the blood routine examination.liver and kidney function were normal level. Nobody withdrew due to adverse events. Conclusion oral contraceptive treatment for endometriosis was more effective,low side effects, especially significant for dysmenorrhea, smaller mass.

关 键 词：避孕药 子宫内膜异位症 疼痛评分 

分 类 号：R711.71[医药卫生—妇产科学]